

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	F)	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/078,090	.090 02/14/2002		Susana Salceda	DEX-0312	5706
26259	7590	10/26/2004		EXAMINER	
LICATLA 66 È. MAIN			BORIN, MICHAEL L		
MARLTON,			ART UNIT	PAPER NUMBER	
				1631	

DATE MAILED: 10/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	055	10/078,090	SALCEDA ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Michael Borin	1631				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - External after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPI MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a re o period for reply is specified above, the maximum statutory perior are to reply within the set or extended period for reply will, by staturely received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).		nely filed is will be considered timely. It the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on 19	August 2004.					
		is action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims		>				
5)□ 6)⊠ 7)□	Claim(s) 1-5,7-9 and 18-21 is/are pending in the application. 4a) Of the above claim(s) 18 is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 1-5,7-9,19-21 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.						
Applicati	on Papers						
	The specification is objected to by the Examin The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the	cepted or b) objected to by the lead of a compared or b) for objected to by the lead in abeyance. See	e 37 CFR 1.85(a).				
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119						
a)[Acknowledgment is made of a claim for foreig All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureative the attached detailed Office action for a list	nts have been received. Ints have been received in Application or ity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment	t(s)						
	e of References Cited (PTO-892)	4) Interview Summary					
3) 🔲 Inforn	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 r No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate atent Application (PTO-152)				

Status of Claims

1. Response filed 08/19/2004 is acknowledged. Claims 6,10-17 are canceled. Claims 18-21 are added. Claims 1-5,7-9,18-21 are pending.

In response to include polynucleotide SEQ ID No. 47, Examiner agrees that there is some overlap in the sequences of two polynucleotides of SEQ ID No. 47 and 48, but maintains that neither specification nor claims identify common core structure necessary for a common utility. The restriction requirements was made final in the previous Office action.

Claim 18 is withdrawn from consideration as drawn to non-elected subject matter.

Claims 1-5,7-9,19-21 are under consideration to the extent they read on the elected subject matter.

Rejections not reiterated from previous Office actions are hereby withdrawn.

The following rejections and/or objections are either reiterated and constitute the complete set presently being applied to the instant application.

Priority

2. Applicant's claim for domestic priority under 35 U.S.C. 119(e) is denied. Applicant demonstrated description of SEQ ID No. 47 in provisional application. However, SEQ ID No. 48, which is the elected subject matter, is not disclosed in the priority application. Partial overlap of a shorter SEQ ID No 47 and much longer

Art Unit: 1631

SEQ ID No. 48 is recognized; however, it is not sufficient to demonstrate that applicant was in possession of polynuceotide SEQ ID No. 48 at the time of filing of the provisional application. Consequently, the claims, as directed to SEQ ID No. 48, are granted priority only to the filing date of instant application.

Claim Objections

3. Claims 1-5, 7-9, 19-21 are objected because they do not reflect the elected subject matter. Applicant elected polynucleotide SEQ ID No. 48 encoding polypeptide SEQ ID No. 151. The claims do not reflect the elected subject matter as they read on SEQ ID No. 47 as well. Amendment of the claims to read on the polynucleotide of SEQ ID 48 is repeatedly requested.

Claim Rejections - 35 U.S.C. § 101/112-1

4. Claims 1-5, 7-9, 19-21 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility due to its not being supported by a specific, substantial, and credible utility or, in the alternative, a well-established utility. The rejection is maintained for the reasons of record and further in view of the following.

Applicant argues that polynucleotide SEQ ID No. 48 is overexpressed in breast cancer tissues. The latter is presumably demonstrated in the Table – see p. 116, line 6. However, it seems that data of the Table are coming straight from the provisional application which does not disclose SEQ ID No. 48 of the instant

Art Unit: 1631

application. See p. 29-33 of the provisional application 60/268999, p. 31, lines 24-27, in particular. Note that the length of the clone comprising, presumably, SEQ ID No. 48, is much shorter (555 bases) than SEQ ID No. 48 itself (1667 bases); also SEQ ID No. 48 described in the provisional application is different from instantly claimed SEQ ID No. 48. Applicant is invited to provide further proof that polynucleotide SEQ ID No. 48 of the instant application is indeed overexpressed in breast cancer tissue.

If polynucleotide SEQ ID No. 48 had been demonstrated to be overexpressed in breast cancer tissues, the utility rejection will be changed to scope of enablement rejection in regard to other nucleic acid molecules encoding amino acid sequence of SEQ ID No. 151.

- 5. Claims 1-5, 7-9, 19-21 are also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by a substantial or a well-established utility for the reasons set forth above, one skilled in the art would not know how to make and/or use the claimed invention.
- 6. Claims 1-5, 7-9 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The rejection is maintained for the reasons of record and further in view of the following.

Applicant argues that providing ATCC deposit number for clone containing SEQ ID No. 48 demonstrates applicant's possession of other elements included in

Art Unit: 1631

DNA. First, as discussed above, length of clones comprising, presumably, SEQ ID No. 48, is much shorter than SEQ ID No. 48 itself. See p. 116, lines 5-8, which demonstrates four clones of various length from 555 to 885, as compared to 1677 bases in SEQ ID No. 48. Second, SEQ ID No. 48 described in the provisional application (Fig.48) is different from instantly claimed SEQ ID No. 48 and the clone containing it does not describe the clone containing SEQ ID No. 48 of the instant application. Therefore the clones do not contain full SEQ ID No. 48, much less any additional elements addressed in the rejection.

Claim Rejections - 35 USC § 102

7. Claims 1-5 remain rejected under 35 U.S.C. 102(a) as being anticipated by the sequence of Accession number BF953475 (01/2001), Database EST or Accession number AL110228, Database GenEmbl. The referenced sequences show more than 95% similarity to regions of SEQ ID No. 48 of the instant invention (see attached sequence alignment). As the referenced sequences have continuous stretches matching the claimed sequence of SEQ ID No. 48 (see attached sequence alignment) it would be expected to selectively hybridize to SEQ ID No. 48, absent evidence to the contrary.

The claims are amended to specify hybridization conditions (claim 1(c)). Calculation of melting temperatures for hybridizing the referenced sequences under the conditions now claimed yields melting temperatures of 70.08°C and 70.53°C, respectively; therefore the referenced sequences will hybridize under the claimed conditions.

The rejection is maintained.

Art Unit: 1631

8. Claims 1-5 remain rejected under 35 U.S.C. 102(a) as being anticipated by Accession number AB040959, Database Genemb (Nagase et al., DNA Research, 7, 143-150, 2000); see attached sequence alignment. The referenced sequences have 96% similarity to polynucleotide encoding polypeptide SEQ ID No. 151.

The claims are amended to specify hybridization conditions (claim 1(c)). Calculation of melting temperatures for hybridizing the referenced sequences under the conditions now claimed yields melting temperatures of 70.73°C; therefore the referenced sequences will hybridize under the claimed conditions.

The rejection is maintained.

Conclusion.

8. No claims are allowed THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will

Art Unit: 1631

the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-0722. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Borin, Ph.D.
Primary Examiner
Art Unit 1631

* * *